Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type

Triggers US$ 9.0 m payment to Evotec

08-Oct-2021 - Evotec SE announced that its collaboration with Bristol Myers Squibb has been expanded to include a new cell type, triggering a payment of $ 9.0 m to Evotec. The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of ...

Evotec launches “PRROTECT”, a pre-competitive initiative to be better prepared for future pandemics

16-Jun-2021 - Evotec SE announced that the Company has launched an initiative for pandemic preparedness (“PRROTECT”). PRROTECT leverages a comprehensive set of novel projects and technologies to be better prepared for and respond faster to viral pandemics of the future. Virus outbreaks that can develop into ...

Bristol Myers Squibb exercises option to extend targeted protein degradation partnership with Evotec

27-Apr-2021 - Evotec SE announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated this strategic drug discovery and development ...

Evotec accelerates access to biologic therapeutics with initiation of manufacturing facility in Toulouse

21-Apr-2021 - Evotec SE announced that the Company has initiated the construction of its J.POD® 2 EU biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® 2 EU, Evotec’s second cGMP biomanufacturing facility, will employ Just – Evotec Biologics’ cutting-edge technology that ...

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

23-Mar-2021 - Evotec SE announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional ...

Evotec achieves milestone in its neurodegeneration collaboration with Bristol Myers Squibb

Evotec receive a US$ 6 m payment

05-Jan-2021 - Evotec SE announced that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio. Evotec and ...

Evotec and Sartorius partner with start-up Curexsys on iPSC-based exosome approach

Exosomes are a promising novel approach for innovative regenerative therapies, as therapeutics in age-related conditions, but also for diagnostic purposes

10-Dec-2020 - Evotec SE Sartorius announced that they have entered into a partnership with the recently established Curexsys GmbH, a Goettingen, Germany-based technology leader specialising in the emerging field of therapeutic exosomes. Curexsys delivers a proprietary isolation technology for exosomes based on ...

Evotec expands Oxfordshire site into a fully-integrated R&D centre

"Dorothy Crowfoot Hodgkin Campus"

13-Nov-2020 - Evotec SE announced the expansion of the Company’s existing campus based at Milton Park in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus. Adding a new building, which will house up to 100 ...

Evotec and Novo Nordisk form alliance to develop novel therapies for kidney diseases

Milestone potential of more than € 150 m per product

19-Aug-2020 - Evotec SE and Novo Nordisk announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease. Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular data sets of ...

Evotec and Secarna form strategic partnership in the field of antisense therapy

Comprehensive agreement for the development of novel antisense oligonucleotide therapeutics across a broad range of targets and indications

06-Aug-2020 - Evotec SE and Secarna Pharmaceuticals GmbH & Co. KG (Secarna) announced a strategic partnership in the field of antisense oligonucleotide (“ASO”)-based therapeutics. Antisense therapy is an innovative, clinically and commercially validated, highly-targeted pharmacological approach which ...